Checkpoint Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2020

Note 8 - Accounts Payable and Accrued Expenses

At December 31, 2020 and 2019, accounts payable and accrued expenses consisted of the following (in thousands):


	December 31,
	2020		2019
Accounts payable	$	3,438	$	3,079
Accrued compensation		535		414
Research and development		2,009		3,496
Other		385		268
Total accounts payable and accrued expenses	$	6,367	$	7,257